Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease
NOWOX Oxygen Therapy Monitoring Device
The purpose of this study is to evaluate the duration of oxygen use recorded by the NOWOX, under usual conditions of daily living, in patients with chronic obstructive respiratory disease requiring oxygen therapy.
- Trial name
- NCT00800072
- Testing
- NOWOX
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Air Liquide SA
Pulmonary Disease, Chronic Obstructive (COPD)
Telemonitoring of Patients With COPD in Carinthia
Evaluation whether the introduction of large-scale telemonitoring of patients with COPD produces benefits in terms of reduced hospital readmissions, improved health related quality of life and health status.
- Trial name
- RenewingHealth (NCT01580072)
- Testing
- self-monitoring for patients with severe COPD, nurse-monitoring for patients with severe COPD
- Where
- 3 sites in Austria
- Volunteers
- 65 people
- Sponsor
- Landeskrankenanstalten-Betriebsgesellschaft
Chronic Obstructive Pulmonary Disease (COPD)
Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary objective of the study is to evaluate structural changes effected by AD9668 in the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice Computed Tomography (MSCT)
- Trial name
- NCT01054170
- Testing
- AZD9668
- Where
- 9 sites in Canada, Denmark and 3 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD)…
- Trial name
- NCT01662986
- Testing
- tiotropium bromide
- Where
- 50 sites in United States
- Volunteers
- 79 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.
- Trial name
- NCT00949975
- Testing
- AZD9668
- Where
- 105 sites in United States, Australia and 10 more
- Volunteers
- 838 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Reliability of a Top Mount Actuation Indicator With Levalbuterol MDI in Adult and Pediatric Subjects With Asthma or COPD
This is a study to investigate the reliability, ruggedness and safety of the top mounted actuation indicator (TMAI) when used with Levalbuterol HFA MDI.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, COPD
- Trial name
- NCT00583986
- Testing
- Levalbuterol HFA MDI with top mounted actuation indicator
- Where
- 26 sites in United States
- Volunteers
- 150 people
- Sponsor
- Sumitomo Pharma America, Inc.
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
- Trial name
- NCT02140346
- Testing
- RV1729 28 day repeat dose
- Where
- 2 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Respivert Ltd
Pulmonary Disease, Chronic Obstructive
Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease
Optimal clinical management in early stages of COPD is not established. Tiotropium has been shown to improve exercise tolerance during (CWR) cycle ergometry with GOLD stage II to IV COPD, improvements in constant speed treadmill…
- Trial name
- NCT01072396
- Testing
- Tiotropium
- Where
- 15 sites in United States, Canada
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-centre, randomised, double-blind, double-dummy, two way cross-over, 12 weeks noninferiority study to evaluate the efficacy, safety, and tolerability of FSC 250/50 mcg capsule-based inhaler and a multi-dose inhaler…
- Trial name
- NCT01978145
- Testing
- FSC
- Where
- 52 sites in Argentina, Mexico and 2 more
- Volunteers
- 665 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)
Primary endpoint: whole lung deposition and in-vivo distribution pattern of a 99mTc-labelled tiotropium powder formulation following inhalation via HandiHalerTM in healthy subjects as well as in patients with mild, moderate and…
- Trial name
- NCT02172456
- Testing
- 99mTc-radiolabelled tiotropium, non-radiolabelled tiotropium
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD
This study is a post-authorization commitment to the European Medicines Agency (EMA). The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the…
- Trial name
- NCT02371629
- Testing
- NVA237, Salbutamol
- Where
- 81 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 776 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Community-acquired Pneumonia
A Pre-post Intervention Study Evaluating Home-based Management of Patients With COPD or CAP
Risk of rehospitalization within 30 days of discharge is higher than 20% in patients with chronic obstructive pulmonary disease (COPD) and up to 20% for patients with community acquired pneumonia (CAP).
- Trial name
- NCT05009485
- Testing
- Current Health platform
- Sponsor
- Current Health
Pulmonary Disease, Chronic Obstructive
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.
- Trial name
- NCT00749411
- Testing
- GSK233705/GW642444
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL administered with 5 microgram tiotropium bromide solution for inhalation, delivered by the Respimat® inhaler, once daily for four weeks in…
- Trial name
- NCT00720499
- Testing
- BI 1744 CL plus tiotropium bromide, Respimat® Inhaler
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 141 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Primary Objective: To investigate effects of SAR440340 (anti-interleukin-33 [IL-33] monoclonal antibody [mAb]) compared with placebo, on the annualized rate of moderate-to-severe acute exacerbations of COPD (AECOPD) over up to 52…
- Trial name
- NCT03546907
- Testing
- SAR440340, Any Inhaled Corticosteroids as prescribed by treating physician as standard of care, Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
- Where
- 83 sites in United States, Argentina and 8 more
- Volunteers
- 343 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
This study was designed to assess the efficacy and long-term safety of 300 and 600 µg doses of indacaterol when delivered via a single-dose dry-powder inhaler (SDDPI) in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00393458
- Testing
- Indacaterol, Formoterol
- Where
- 183 sites in Argentina, Chile and 23 more
- Volunteers
- 1,732 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease (COPD)
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
The purpose of this study was to evaluate the efficacy, safety, and tolerability of single doses of trospium inhalation powder (TrIP) administered to subjects with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00801684
- Testing
- TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Alkermes, Inc.
COPD Patients
EarlySense Monitoring Device Evaluation on COPD, CHF and Pneumonia Patients
Continuous measurement of breathing patterns, heart rate, restlessness and cough in sleep using EarlySense ES 16 device. Predicting worsening in COPD patients' condition using the above parameters.
- Trial name
- NCT00361426
- Testing
- Earlysense vital sign monitor
- Where
- Israel
- Sponsor
- EarlySense Ltd.
Pulmonary Disease, Chronic Obstructive, Lung Diseases
A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease
PF-03635659 is being developed for the treatment of chronic obstructive pulmonary disease. This is a study to examine the safety, pharmacokinetics and pharmacodynamics of PF-03635659 in patients with Chronic Obstructive Pulmonary…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Lung Diseases, Respiratory Tract Diseases, Chronic Obstructive Airway Disease
- Trial name
- NCT01033487
- Testing
- active comparator, Low Dose PF-03635659, Mid Dose PF-03635659
- Where
- Germany
- Volunteers
- 22 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD
To demonstrate the free combination of budesonide and indacaterol is as efficacious as fluticasone and salmeterol in patients with COPD
- Trial name
- COMBINE (NCT02055352)
- Testing
- Budesonide, Fluticasone, Indacaterol
- Where
- 25 sites in Argentina, Brazil and 6 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.